<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-rchp-1l-dlbcl-bobes">
    <meta name="study:title" content="PB3252 - Polatuzumab-R-CHP in previously untreated diffuse large B-cell lymphoma. A retrospective study.">
    <meta name="study:fileName" content="Abstracts/POLA-RCHP-1L-DLBCL-BOBES.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence"> <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Prednisone,Chemotherapy,CIT,Pola-RCHP">

    <title>PB3252: Pola-R-CHP in 1L DLBCL (Bobes) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3252 - Pola-R-CHP in Previously Untreated DLBCL (Retrospective)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=38)</h4>
                    <p>Previously untreated DLBCL (>18 yrs). Aim: Assess Pola-RCHP effectiveness & safety in real-world.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pola-RCHP)</h4>
                    <p>Pola-RCHP as first-line therapy. Multicenter (9 Spanish centers) retrospective study.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=34 Evaluable)</h4>
                    <p>ORR: <span class="highlight-value">88%</span><br>CRR: <span class="highlight-value">85%</span><br>4 Pts experienced PD.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>No TRDs. Febrile Neutropenia (21%). Supports POLARIX findings in real-world.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3252 - Polatuzumab-R-CHP in previously untreated diffuse large B-cell lymphoma. A retrospective study.</h1>
            <p class="abstract-sub-header">Alejandro Bobes, Laura Llorente, Virginia Pradillo, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3252 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>DLBCL is the most prevalent NHL; R-CHOP was the established treatment.</li>
                        <li>Polatuzumab Vedotin (Pola), an anti-CD79b ADC, with R-CHP (Pola-RCHP) approved for 1L DLBCL based on POLARIX trial.</li>
                        <li>Limited experience with Polatuzumab in daily practice.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To assess effectiveness (response rates), safety (CTCAE NCI v5.0), and follow-up outcomes of Pola-RCHP in previously untreated DLBCL.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective, multicenter (9 Spanish centers), descriptive study (15-MDA-LNH-2023).</li>
                        <li>Enrollment Period: Oct 2023 - Jan 2025.</li>
                        <li>Inclusion: >18 years, diagnosed DLBCL, treated with 1L Pola-RCHP (outside clinical trials).</li>
                        <li>Response Assessment: PET-CT (IWG 2007 criteria).</li>
                        <li>Toxicity: CTCAE v5.0. Analysis: SPSS.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Real-World Study Overview</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=38)</strong>
                            <span>Previously Untreated DLBCL (>18 yrs)</span>
                            <span>(9 Spanish Centers, Oct 2023 - Jan 2025)</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Treatment Received</strong>
                                <span>Frontline Pola-R-CHP</span>
                                <span>(Total 211 cycles administered)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Response (ORR, CRR by IWG 2007)</span>
                           <span>Safety (CTCAE v5.0)</span>
                           <span>Follow-up Outcomes</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=38)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Male, n (%)</td><td>26 (68.4%)</td></tr>
                                <tr><td>Median Age, years (range)</td><td>58 (36-85)</td></tr>
                                <tr><td>ECOG PS 0-1, %</td><td>92%</td></tr>
                                <tr><td>GCB Subtype, %</td><td>45%</td></tr>
                                <tr><td>ABC Subtype, %</td><td>42%</td></tr>
                                <tr><td>Ann Arbor Stage III-IV, %</td><td>81%</td></tr>
                                <tr><td>IPI Score 1-2, %</td><td>55%</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (N=34 Evaluable for Response)</h2>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">ðŸ“Š</div>
                            <div class="infographic-value">88%</div>
                            <div class="infographic-label">Overall Response Rate (ORR)</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">ðŸŽ¯</div>
                            <div class="infographic-value">85%</div>
                            <div class="infographic-label">Complete Response (CR) Rate</div>
                        </div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>4 patients experienced disease progression during follow-up (at 8.5, 6.8, 6, and 3.5 months).</li>
                    </ul>
                     <div class="km-plot-container zoomable-image-container"> <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PB3252_Fig1_Swimmer.png" alt="Figure 1: Swimmer Plot of Patient Outcomes" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=Swimmer+Plot+Not+Available';">
                        <p class="text-xs text-center mt-1">Figure 1: Swimmer Plot of Patient Outcomes (Adapted from Abstract)</p>
                    </div>
                </div>
            </div>
        </div>
        
        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Safety Summary (N=38)</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2 safety-table">
                <li>No treatment-related deaths.</li>
                <li>One dose reduction (due to recurrent febrile neutropenia).</li>
                <li>GCSF for primary prophylaxis: 86% of patients.</li>
                <li>Cycle delays: 19/211 cycles (9%), primarily due to neutropenia.</li>
                <li><strong>Most Common Side Effects (% of patients):</strong>
                    <ul class="list-circle list-inside ml-4">
                        <li>Febrile Neutropenia: 21%</li>
                        <li>Anemia: 10%</li>
                        <li>Respiratory Infections: 10%</li>
                        <li>Peripheral Neuropathy: 8%</li>
                    </ul>
                </li>
            </ul>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This real-world study supports the effectiveness and safety of Pola-RCHP observed in the POLARIX phase 3 trial.</li>
                <li>The study is ongoing for further expansion and continued follow-up.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>ABC, Activated B-Cell like; ADC, Antibody-Drug Conjugate; AE, Adverse Event; CHOP-R, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab; CIT, Chemoimmunotherapy; CR, Complete Response; CTCAE NCI, Common Terminology Criteria for Adverse Events National Cancer Institute; DLBC, Diffuse Large B-Cell; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GCB, Germinal Center B-cell like; GCSF, Granulocyte Colony-Stimulating Factor; IPI, International Prognostic Index; IWG, International Working Group; MDA, Multicenter Descriptive Analysis; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; PET-CT, Positron Emission Tomography-Computed Tomography; Pola, Polatuzumab Vedotin; Pola-RCHP, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; SPSS, Statistical Package for the Social Sciences; TRD, Treatment-Related Death.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Bobes A, Llorente L, Pradillo V, et al. Polatuzumab-R-CHP in previously untreated diffuse large B-cell lymphoma. A retrospective study. Abstract #PB3252 presented at European Haematology Association (EHA) June 12â€“15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3252 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
            <p>Study ID: 15-MDA-LNH-2023 | For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    </body>
</html>
